Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study.

Sofia VolpatoSara MontagneseAlberto ZanettoMatteo TurcoMichele De RuiAlberto FerraresePiero AmodioGiacomo GermaniMarco SenzoloMartina GambatoFrancesco Paolo RussoPatrizia Burra

Published in: BMJ open gastroenterology (2017)

Some degree of neuropsychiatric impairment was observed in relation to treatment with DAAs in patients with cirrhosis, but not in post-LT patients, suggesting that the former may be sensitive to mild DAA neurotoxicity.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
combination therapy
patient reported outcomes